Drug Trial Radar · NCT07600905
Avatrombopag Versus Standard Care for Low Platelet Counts After Liver Transplant
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
245
Actual
Start
Nov 1, 2019
Primary completion
Aug 31, 2025
Study completion Aug 31, 2025
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 22, 2026
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This retrospective cohort study evaluated adult recipients of liver transplantation (LT) who developed severe post-transplantation thrombocytopenia, defined as a platelet count below 30 x 10\^9/L within 7 days after LT, at a single centre in China between November 2019 and August 2025. Participants received either avatrombopag or standard care. Avatrombopag was given orally at 40 mg once daily for 5 days, started when the postoperative platelet count fell below 30 x 10\^9/L. Standard care included recombinant human thrombopoietin. The primary objective was to compare the rate of platelet count recovery between the two groups. Secondary objectives were to compare blood product use and 30-day complications. A total of 245 eligible participants were identified; 70 received avatrombopag and 175 received standard care. One-to-two propensity score matching produced an analysis cohort of 70 avatrombopag recipients and 140 matched controls. The hypothesis was that avatrombopag would accelerate platelet recovery and reduce transfusion requirements without increasing thrombosis.
Conditions
- Postoperative Complication
- Severe Thrombocytopenia
- Liver Transplantation (LT)
Interventions
Avatrombopag 40 mg oral tabletDrug
Avatrombopag administered orally at 40 mg once daily for 5 days, initiated when the postoperative platelet count fell below 30 x 10\^9/L after liver transplantation. The 40 mg daily dose was given as two 20 mg tablets. Dose and duration followed the approved regimen for chronic liver disease in the ADAPT-1 and ADAPT-2 trials.
Recombinant Human Thrombopoietin(rhTPO)Drug
Recombinant human thrombopoietin administered subcutaneously at 15,000 IU once daily as part of standard care, initiated at the treating physician's discretion when the platelet count fell below 30 x 10\^9/L, for 14 days or until the platelet count reached 100 x 10\^9/L or higher. Administered to all controls and to 42 of 70 avatrombopag-treated participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- platelet rise rateTime frame: 30 days post-Liver transplatation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.